Stacy Loeb, MD
Genomic testing can be a useful tool in helping to ensure accurate risk stratification prior to selecting a treatment for patients with prostate cancer, says Stacy Loeb, MD.
at AUA, Loeb, an assistant professor of Urology and Population Health at NYU Langone Medical Center, discussed the promise and challenges with genomic testing in prostate cancer.
OncLive: Can you please provide an overview of the study you presented investigating the Decipher test?
Active surveillance is a growing management option. The new AUA guidelines just said that it is the best option and is preferred for patients with very low-risk prostate cancer. This has hit the primetime.
... to read the full story